Technical Analysis for VTYX - Ventyx Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.44 | -3.58% | -0.17 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | -3.58% | |
| Wide Bands | Range Expansion | -5.73% | |
| Wide Bands | Range Expansion | -8.45% | |
| Gapped Up | Strength | -8.45% | |
| Upper Bollinger Band Touch | Strength | -8.45% | |
| Wide Bands | Range Expansion | -9.57% |
| Alert | Time |
|---|---|
| Possible NR7 | about 9 hours ago |
| 20 DMA Support | about 14 hours ago |
| Down 3% | about 14 hours ago |
| Fell Below Previous Day's Low | about 14 hours ago |
| Down 2 % | about 14 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
Ventyx Biosciences, Inc. Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Autoimmune Disease Inflammatory Diseases Psoriasis Inflammatory Bowel Disease Ulcerative Colitis Autoimmune Disorders Cytokine Lupus Immune Mediated Diseases Molecule Product Psoriatic Arthritis Inflammasome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 40.5785 |
| 52 Week Low | 1.865 |
| Average Volume | 2,062,356 |
| 200-Day Moving Average | 13.19 |
| 50-Day Moving Average | 6.00 |
| 20-Day Moving Average | 4.42 |
| 10-Day Moving Average | 4.38 |
| Average True Range | 0.42 |
| RSI (14) | 44.13 |
| ADX | 18.83 |
| +DI | 23.64 |
| -DI | 24.71 |
| Chandelier Exit (Long, 3 ATRs) | 3.97 |
| Chandelier Exit (Short, 3 ATRs) | 4.97 |
| Upper Bollinger Bands | 5.07 |
| Lower Bollinger Band | 3.78 |
| Percent B (%b) | 0.51 |
| BandWidth | 29.22 |
| MACD Line | -0.24 |
| MACD Signal Line | -0.35 |
| MACD Histogram | 0.1135 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.77 | ||||
| Resistance 3 (R3) | 4.79 | 4.71 | 4.72 | ||
| Resistance 2 (R2) | 4.71 | 4.62 | 4.70 | 4.70 | |
| Resistance 1 (R1) | 4.57 | 4.57 | 4.53 | 4.55 | 4.68 |
| Pivot Point | 4.49 | 4.49 | 4.47 | 4.48 | 4.49 |
| Support 1 (S1) | 4.35 | 4.40 | 4.31 | 4.33 | 4.20 |
| Support 2 (S2) | 4.27 | 4.35 | 4.26 | 4.18 | |
| Support 3 (S3) | 4.13 | 4.27 | 4.17 | ||
| Support 4 (S4) | 4.11 |
